CAR-T

#EBMT / The Success Story of Equecabtagene Autoleucel: The World’s First Fully Human CAR-T for Multiple Myeloma

#EBMT / The Success Story of Equecabtagene Autoleucel: The World’s First Fully Human CAR-T for Multiple Myeloma In recent years, CAR-T cell therapy has made groundbreaking progress in the field of relapsed/refractory multiple myeloma (RRMM), offering hope to patients struggling with limited treatment options. Recent data shows that Equecabtagene Autoleucel achieved an impressive complete response (CR) Read More

July 5th,2024 CAR-T , Myeloma

Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient

### Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient | Successful Case from The First Affiliated Hospital of Chongqing Medical University On November 7, 2023, China’s first CAR-T product for treating adult leukemia, Yuan Ruida (Inaticabtagene Autoleucel Injection), was officially approved for market release. This marks a significant breakthrough Read More

July 4th,2024 CAR-T , Leukemia

Three Major Reasons and Process to Choose Medical Treatment in China

Three Major Reasons and Process to Choose Medical Treatment in China ### High-Quality Medical Care In recent years, China’s medical technology has made significant strides, achieving a strong and leading position globally. China boasts advanced medical technologies and equipment, with many hospitals offering world-class diagnostic and treatment capabilities. Patients who travel to China for medical Read More

July 3rd,2024 CAR-T

One Year After Approval: How Effective is China’s First BCMA-Targeted CAR-T Therapy in Treating Multiple Myeloma?

### One Year After Approval: How Effective is China’s First BCMA-Targeted CAR-T Therapy in Treating Multiple Myeloma? “In the past 20 years, the treatment of multiple myeloma has advanced rapidly, thanks in large part to the swift progress in drug development. Over the past year, China’s first independently developed and the world’s first fully human Read More

July 2nd,2024 CAR-T

IASO Bio’s Equecabtagene Autoleucel Injection Wins “China First-in-Class” Award, Showcasing China’s Biopharmaceutical Innovation

**IASO Bio’s Equecabtagene Autoleucel Injection Wins “China First-in-Class” Award, Showcasing China’s Biopharmaceutical Innovation** On June 28, 2024, at the “2024 First CBA-China Annual Conference” hosted by the Chinese Biopharmaceutical Association, USA, at the Suzhou International Expo Centre, IASO Bio’s Equecabtagene Autoleucel Injection was honored with the “China First-in-Class Targeted Drug” award. This award recognizes the Read More

July 1st,2024 CAR-T

**2024 ASCO: National Institute’s New CAR-T Therapy CD7 CAR-T Cells, Multiple Blood Cancer Destroyers**

**2024 ASCO: National Institute’s New CAR-T Therapy CD7 CAR-T Cells, Multiple Blood Cancer Destroyers** **2024 ASCO: Four Chinese-developed CAR-T therapies make a significant impact, targeting colorectal cancer, pancreatic cancer, and hematological tumors, with an overall response rate nearing 100.0%**   **CD7 CAR-T Cells: A Powerful Strike Against Hematological Tumors, Patients Achieve Complete Remission**   Patients Read More

June 27th,2024 CAR-T

Thérapie révolutionnaire apporte un nouvel espoir : le patient suisse Thomas commence le traitement CAR-T à l’hôpital Tongji de Wuhan

**Thérapie révolutionnaire apporte un nouvel espoir : le patient suisse Thomas commence le traitement CAR-T à l’hôpital Tongji de Wuhan** L’équipe du professeur Li Chunrui de l’hôpital Tongji de Wuhan a mené avec succès un cas de thérapie immunitaire à cellules T à récepteur antigénique chimérique (CAR-T) pour un patient atteint de myélome multiple récurrent Read More

June 21st,2024 CAR-T

Breakthrough Therapy Brings New Hope: Swiss Patient Thomas Begins CAR-T Treatment at Tongji Hospital, Wuhan

**Breakthrough Therapy Brings New Hope: Swiss Patient Thomas Begins CAR-T Treatment at Tongji Hospital, Wuhan** Professor Li Chunrui’s team at Tongji Hospital in Wuhan successfully conducted a case of chimeric antigen receptor T-cell (CAR-T) immunotherapy for a patient with relapsed and refractory multiple myeloma, offering new life to Swiss patient Thomas. Thomas, a 54-year-old patient Read More

June 21st,2024 CAR-T

Pioneering Chinese Medical Team: Intranasal Neural Stem Cell Transplantation for Parkinson’s Disease, Clinical Trial a Great Success!

**Pioneering Chinese Medical Team: Intranasal Neural Stem Cell Transplantation for Parkinson’s Disease, Clinical Trial a Great Success!** **Breakthrough Research** The expert team at Peking Union Medical College Hospital (PUMCH) has conducted the world’s first clinical trial (ANGE-S003) using intranasal human neural stem cell transplantation to treat Parkinson’s disease, yielding promising results and offering new hope Read More

June 18th,2024 CAR-T

Treatment Options for Lymphoma

Blood cancers, including lymphoma, are extremely heterogeneous and can involve a variety of treatment options, often in combination. Some form of chemotherapy, radiation therapy, immunotherapy, or a combination is typically used to treat Hodgkin lymphoma. Bone marrow or stem cell transplantation may also sometimes be done under special circumstances. Most patients with Hodgkin lymphoma live Read More

June 12th,2024 CAR-T

Non-Hodgkin Lymphoma

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are cancers that affect lymphocytes. CLL and SLL are essentially the same diseases, with the only difference being the location where the cancer primarily occurs. When most of the cancer cells are located in the bloodstream and the bone marrow, the disease is referred to as Read More

June 12th,2024 CAR-T

Hodgkin Lymphoma

Hodgkin Lymphoma (HL), also known as Hodgkin disease, is a type of cancer that affects the lymphatic system, usually found in the lymph nodes. HL is characterized by the presence of very large cells called Reed-Sternberg (RS) cells, although other abnormal cell types may be present. HL usually starts in the lymph nodes; however, it Read More

June 12th,2024 CAR-T